Venetoclax (Venclexta) uye rituximab (Rituxan) anoshandiswa pamwe chete nekudzoka zvakare / refractory chronic lymphocytic leukemia ( CLL ), zvichikonzera mwero wakakwira wezvisingaonekwe zvishoma zvasara chirwere ( uMRD ), Iyo inosanganisirwa nehurefu hwekuenderera-husina kupona ( PFS ).
Varwere veVenetoclax uye rituximab-vakarapwa vaive nekashanu nguva yeMRD chinzvimbo chakabatanidzwa ne phenytoin uye rituximab, uye chikamu chevarwere vakachengeta chinzvimbo ichi pamwedzi makumi maviri nemana yaive yakakwira muboka revenetoclax / rituximab iro makumi maviri kana anopfuura nguva. Zvichienzaniswa neMRD- yakanaka mamiriro, uMRD yaibatanidzwa ne 5% kudzikira munjodzi yekufambira mberi kwechirwere kana kufa.
Chimiro cheMRD chakaratidza kufanotaura PFS muvarwere veCLL vanorapwa ne chemoimmunotherapy, asi kukosha kwekufungidzira kweMRD yemishonga mitsva kunoramba kusinganyatsozivikanwi. Dhata kubva kune yakasarudzika MURANO kuyedza inopa mukana wekuongorora kukosha kwekufungidzira kweMRD neCLL pasina chemotherapy.
MURANO chikamu chechitatu cheyakaedzwa chiedzo ichiongorora kushanda kwe rituximab inosanganisirwa ne venetoclax inopesana ne bendamustine muvarwere ve389 vakadzokerazve / vanodzora CLL. Murwere akagashira 2 makore e venetoclax uye yekutanga 6 mwedzi ye rituximab, kana mwedzi mitanhatu ye bendamustine pamwe ne rituximab kwemwedzi mitanhatu.
Ongororo yekutanga yakaratidza kuti ichienzaniswa nerituximab uye bendamustine, njodzi yekuwedzera kwechirwere kana kufa yaive 84% pamakore matatu ekurapwa nevenetoclax uye rituximab.
